BRISTOL, Tenn., Nov. 9 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) today reported that the Company intends to file a Form 12b-25
with the U.S. Securities and Exchange Commission ("SEC") providing for a five
calendar-day extension for submitting its Form 10-Q for the quarter ended
September 30, 2004. As previously announced, King is in the process of
evaluating its historical reserve for returns of the Company's products.
Although King currently intends to file its Form 10-Q on Monday, November 15,
2004, it is possible that the Company will not complete its returns reserve
evaluation in time to file within the extension period.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
About Forward-looking Statements
This release contains forward-looking statements which reflect
management's current views of future events and operations, including, but not
limited to, statements pertaining to the anticipated filing of King's Form 10-
Q for the third quarter ended September 30, 2004. These forward-looking
statements involve certain significant risks and uncertainties, and actual
results may differ materially from the forward-looking statements. Some
important factors which may cause actual results to differ materially from the
forward-looking statements include: dependence on the time required to
complete the evaluation of the Company's historical reserve for returns; and
dependence on King's ability to file the Company's Form 10-Q for the third
quarter ended September 30, 2004 within the five calendar-day extension
period. Other important factors that may cause actual results to differ
materially from the forward-looking statements are discussed in the "Risk
Factors" section and other sections of King's Form 10-K for the year ended
December 31, 2003 and Form 10-Q for the second quarter ended June 30, 2004
which are on file with the SEC. King does not undertake to publicly update or
revise any of its forward-looking statements even if experience or future
changes show that the indicated results or events will not be realized.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs of King Pharmaceuticals, Inc., +1-423-989-8125
|
